コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ations of ARVC are associated with different prognoses.
2 revealed two classes with clearly different prognoses.
3 ts of MYC and either BCL2 or BCL6, face poor prognoses.
4 ents with varying clinical presentations and prognoses.
5 s, which could contribute to their divergent prognoses.
6 t therefore be used in determining patients' prognoses.
7 alpha (ERalpha)-positive tumors and disease prognoses.
8 ratify patients with significantly different prognoses.
9 d for individualizing therapy and predicting prognoses.
10 lt acute myeloid leukemia patients with poor prognoses.
11 occurs in favorable and unfavorable disease prognoses.
12 where its expression is associated with poor prognoses.
13 natures were prominent in patients with good prognoses.
14 c NSCLC hold inaccurate perceptions of their prognoses.
15 essed in tumors from patients with favorable prognoses.
16 s were interviewed in the hospital to elicit prognoses.
17 ents often have different views of patients' prognoses.
18 and multiorgan failure, which all carry poor prognoses.
19 ents were among patients with poorer initial prognoses.
20 effects in subgroups known to have different prognoses.
21 ons of patients with specific physiology and prognoses.
22 ern divides GBM in two groups with differing prognoses.
23 se, and renal disease have particularly poor prognoses.
24 izures but each is associated with different prognoses.
25 aggressive malignancies that have very poor prognoses.
26 amplification, which have particularly poor prognoses.
27 vein, lymph nodes, or lungs, leading to poor prognoses.
28 epressed patients who predominantly had poor prognoses.
29 be used to aid in establishing diagnoses and prognoses.
30 re similarities with breast tumors with good prognoses.
31 cation of subtypes associated with different prognoses.
32 e development of novel treatments and better prognoses.
33 atasets of human NE tumors with good or poor prognoses.
34 a strong cough, or who are awake have better prognoses.
35 y poor outcomes in a group with already poor prognoses.
36 a diverse group of lung diseases with varied prognoses.
37 t birth and have only limited treatments and prognoses.
38 hort course in a group of patients with poor prognoses.
39 System intermediate-2/high, or >10% blasts) prognoses.
40 has multiple disease variants with different prognoses.
41 s (96.5%), physicians were able to formulate prognoses.
42 omparison of the formulated and communicated prognoses.
43 ovascular membranes having particularly poor prognoses.
44 P, Caspase-8, and FADD had particularly poor prognoses.
45 hese levels with disease characteristics and prognoses.
46 ith heterogeneous clinical presentations and prognoses.
47 ves are needed for those with less favorable prognoses.
48 as fixed abutments resulted in worse initial prognoses.
49 that a sample comprised patients with poorer prognoses.
50 and communication of multiple datasets with prognoses.
51 cancers that are often associated with poor prognoses.
52 ertain appropriateness for those with longer prognoses.
53 immune environment, often resulting in poor prognoses.
54 ential biomarker relevant to various disease prognoses.
55 efractory or relapsed (R/R) tumors face poor prognoses.
56 treatment strategies for patients with poor prognoses.
57 antation have few treatment options and poor prognoses.
58 VO and CRVO may predict long-term functional prognoses.
59 early childhood onset and potentially fatal prognoses.
60 le-refractory) have limited options and poor prognoses.
61 ical manifestations, treatment responses and prognoses.
62 1 correlate with poor-glioblastoma patients' prognoses.
63 solid organ malignancies and portends worse prognoses.
64 birth antecedents, clinical correlates, and prognoses.
65 ry to treatment and accompanied by worsening prognoses.
66 ubgroups with distinct clinical features and prognoses.
67 atures in association with distinct clinical prognoses.
68 s, leading to different tumor phenotypes and prognoses.
69 Bile duct tumors are rare and have poor prognoses.
70 which are associated with distinct clinical prognoses.
71 ciated with adverse short-term and long-term prognoses.
72 ranging from ecosystem stability to medical prognoses.
73 particular among patients with initial worse prognoses.
74 patients diagnosed with cancers with poorer prognoses.
75 the oncogenic phenotype in tumors with poor prognoses.
76 and multiple sites associated with the worst prognoses.
77 ed therapies for patients with SCC with poor prognoses.
78 y slides cannot accurately predict patients' prognoses.
79 normalities, gene expression signatures, and prognoses.
80 3%, P = .08) seemed associated with the best prognoses.
81 healthcare professionals estimate patients' prognoses.
82 , includes four subtypes with very different prognoses.
83 pes of sepsis and ARDS that confer different prognoses.
84 s and differences in beliefs about patients' prognoses.
85 CMO were critically ill with similar guarded prognoses.
86 eterogeneity correlates with cancer clinical prognoses.
87 any tumor types correlates with poor patient prognoses.
88 urvival forest was used to determine patient prognoses.
89 eir children's developmental and psychiatric prognoses.
90 mmunomodulatory treatment and have different prognoses.
91 stically optimistic expectations about their prognoses.
92 activation, DCBLD2 phosphorylation, and poor prognoses.
93 tion rates and suffered diminished long-term prognoses.
94 tcome assessment, therapeutic responses, and prognoses.
95 n particular among those with poorer initial prognoses.
97 oagulopathy (DIC), which correlate with poor prognoses.(2)(,)(3)(,)(4) Here, we demonstrate that a ne
99 nt clinical activity despite poor risk-based prognoses, achievement of minimal residual disease in so
100 man IPF patients and is correlated with poor prognoses, advanced disease states and worse fibrotic ou
101 have changed over time, and thus altered the prognoses after MI, especially the risk for the developm
102 g system allowed for enhanced post-operative prognoses after tumour-resection surgeries in rats.
103 sly adequate cancer treatments and favorable prognoses, almost half of the patients experienced a pos
104 nflammatory disease are associated with poor prognoses, along with insufficient control of risk facto
105 ve contributed to homogenizing MSSA and MRSA prognoses, although the specific rifampin combinations m
106 A methyltransferase 3alpha (DNMT3A) and poor prognoses among acute myeloid leukemia (AML) patients.
107 phenotype, explaining in part the disparate prognoses among medulloblastoma subtypes and suggesting
109 cations may lead to more targeted diagnoses, prognoses and clinical treatment decisions via molecular
110 on was shown to strongly correlate with poor prognoses and decreased survival in pancreatic cancer pa
111 s about physicians' assessments of patients' prognoses and differences in beliefs about patients' pro
114 be due to selection of patients with better prognoses and further stresses the importance of complet
115 vidualized treatment monitoring for improved prognoses and has potential as an early surrogate endpoi
116 tified patients into subgroups with distinct prognoses and identified a high-risk patient group featu
117 f LGG that may identify patients with better prognoses and increased chance of responding to therapy.
121 learly identifies 3 subgroups with different prognoses and may be helpful for therapeutic decisions.
122 enarios, which are associated with different prognoses and might require different treatment strategi
123 deemed appropriate for patients with shorter prognoses and of uncertain appropriateness for those wit
126 e CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later conso
129 vance care planning, the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea
130 of 9,105 patients in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea
131 rticipating sites in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea
132 % women) enrolled in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea
133 of 9,105 patients in the Study to Understand Prognoses and Preferences for Outcomes and Risks of Trea
134 Subjects were from the Study to Understand Prognoses and Preferences for Risks of Treatments (SUPPO
135 fter adjustment for differences in patients' prognoses and preferences, older age was associated with
136 inguish between them, as they have different prognoses and require different management approaches.
138 blastoma subtypes characterized by different prognoses and responses to treatment would greatly facil
140 th localised disease can have very different prognoses and treatment options, ranging from observatio
142 ers are divided into subtypes with different prognoses and treatment responses based on global differ
144 ression models indicated that improvement in prognoses and worsening in prognoses were both strongly
145 Fifty-two were hematogenous, with poorer prognoses, and 88% were caused by methicillin-susceptibl
146 es, detection of cancers with more favorable prognoses, and improved performance outcomes versus DM.
148 group-level explanations, clinically useful prognoses, and precision medicine approaches that are tr
149 ed to personalise treatment, make diagnoses, prognoses, and predict adverse outcomes resulting from t
150 tically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknow
154 e clinical factors used in the assignment of prognoses are clearly associated with changes in clinica
156 of molecularly targeted therapies means that prognoses are far poorer for those with disseminated or
160 ts with different immune response states and prognoses, as well as revealing the role of underlying g
162 s made for sociodemographic characteristics, prognoses, baseline function, patients' preferences for
163 outcome of ALF varies by etiology, favorable prognoses being found with acetaminophen overdose, hepat
164 ncer is a heterogeneous disease with diverse prognoses between left-sided and right-sided patients; t
165 ver tissues from 56 HCC patients with better prognoses (BHCC, >/=5-year survival) and 58 with poor pr
166 CLL patients into 2 subgroups with different prognoses, but it does not consider the pattern of CD49d
169 ts can improve the accuracy of diagnoses and prognoses, can improve the accuracy of genetic counselin
170 38 of 340] vs 68.5% [37 of 54]) and had poor prognoses characteristics (32.6% [76 of 233] vs 25.0% [n
173 creased accuracy, and more easily understood prognoses compared with conventional staging, allow for
174 e mechanisms underlying the observed adverse prognoses conferred by diagnosis of upper gastrointestin
175 e differing risk factor profiles and diverse prognoses demonstrate the potential importance of a stra
178 stintervention estimates of patients' 1-year prognoses did not differ between intervention and contro
179 l nervous system tumors carry grave clinical prognoses due to limited effectiveness of surgical resec
180 may be preferred for patients with favorable prognoses, ECMO for patients with hemodynamic compromise
181 Hyperdiploidy and subgroups with favorable prognoses exhibited notable sensitivities to asparaginas
182 luded improved statistical power and refined prognoses for a range of respiratory, infectious, autoim
183 tively, results indicate dramatic changes in prognoses for adult kidney transplant candidates, likely
185 trate characteristics predicting the poorest prognoses for patients requiring prolonged mechanical ve
186 strategies and the provision of quantitative prognoses for patients undergoing epilepsy surgery.
187 nd disease progression, enables personalized prognoses for patients with chronic wounds, and has the
196 han 10 years and cancers with very favorable prognoses (Gleason score of 3 or 4 and prostate-specific
197 fferential responses to treatment and varied prognoses have long suggested myriad underlying causes.
199 orted that their beliefs about the patients' prognoses hinged exclusively on prognostic information p
200 With the exception of patients with the best prognoses, however, the cost-effectiveness of initiating
202 tic osteosarcoma, the group with unfavorable prognoses, identified by Pgp expression, performed well
203 angements and can help patients with limited prognoses identify their end-of-life goals and preferenc
204 burden now lies with estimating neurological prognoses in a large number of patients who were initial
209 phocytes (TILs) are correlated with positive prognoses in cancer patients and are used to determine t
211 trkB expression is associated with different prognoses in neuroblastoma, our study indicates that the
214 thelial growth factor (VEGF) levels and poor prognoses in patients with solid tumors and acute leukem
215 G expression correlated with poorer clinical prognoses in several human cancers, and C/EBPgamma deple
217 wide and the robust associations with better prognoses in triple-negative breast cancer (TNBC) and HE
218 knowledge when estimating their loved ones' prognoses, including individualized attributes of the pa
219 ributed to their beliefs about the patients' prognoses, including perceptions of the patient's indivi
221 that the traditional approach for assigning prognoses is ineffective for teeth with an initial progn
222 the acquisition of lymphomas with favorable prognoses is negated through an increased mortality from
224 homa (ATL) are aggressive diseases with poor prognoses, limited therapeutic options, and no curative
226 resent study showed that teeth with hopeless prognoses might be retained by decreasing probing depths
227 ts were independently associated with better prognoses (odds ratio 0.12, 95% confidence interval 0.03
228 atients (>60 years old), characteristics and prognoses of adult iTTP patients enrolled in the French
232 s unclear whether statin use increases risk; prognoses of diabetes after exposure require further cla
234 vantages of the ITA.LI.CA staging system for prognoses of liver cancer developed by Alessandro Vitale
236 such as the superimposed acute illness, the prognoses of other patients cared for by the same physic
238 istologic classification system to determine prognoses of patients with alcoholic hepatitis (AH).
239 ete understanding of disease mechanisms, the prognoses of patients with Behcet syndrome, including th
242 ces treated with citric acid can enhance the prognoses of teeth with periodontal lesions as measured
243 epidemiology, clinical characteristics, and prognoses of the less common malignant diseases of the u
245 escribed models are seldom used to determine prognoses of these patients, partially because they have
246 ncreatic cancer, assist in the diagnoses and prognoses of this disease, and develop novel therapies.
247 state cancers exhibited the poorest clinical prognoses on both univariable and multivariable analyses
248 linical syndromes, triggering pathogens, and prognoses; one-third have viral or non-infectious proces
249 ver, in a subgroup of CLL patients with good prognoses or early-stage disease (Rai stages 0-II, Binet
251 nts with advanced medical illnesses and poor prognoses, overuse of invasive intensive care unit (ICU)
252 ing depths (P < 0.0001), significantly worse prognoses (P < 0.0001), and significantly worse mobility
254 (BHCC, >/=5-year survival) and 58 with poor prognoses (PHCC, <5-year survival) after partial liver r
255 lopmental trajectories is crucial for making prognoses, planning interventions, and monitoring progre
257 ng solid organ transplantation had excellent prognoses, reflecting selection incorporating existing g
259 .006) significantly improved the accuracy of prognoses relative to clinical characteristics alone (eg
261 rcations of multi-rooted teeth with hopeless prognoses seems to be a viable alternative to accessing
263 ed satellite lesions or local recurrence had prognoses similar to those of patients with stage III di
264 he first landmark but met the second one had prognoses similar to those who failed both landmarks.
265 in the first year and for those with poorer prognoses, such as those newly diagnosed with heart fail
267 eloped IBTR or oLRR had significantly poorer prognoses than patients who did not experience these eve
268 microsatellite instability (MSI) have better prognoses than patients with tumors without MSI, but hav
270 Patients referred to this bridge program had prognoses that are significantly better than those of pa
271 s, many patients continue to experience poor prognoses that include recurrent fractures and mortality
272 ent of a more effective method for assigning prognoses that is based on clear, objective clinical cri
273 ans identified uncertainty about recipients' prognoses, the perception that palliative care precludes
274 ukemia (AML) and confer relatively favorable prognoses, these cytogenetic groups are often treated si
275 We hypothesize that lncRNAs modulate HCC prognoses through differential deregulation of key lncRN
276 pecifically described communicating terminal prognoses to patients only when specific preferences for
277 ventilation will help physicians communicate prognoses to patients or surrogate decision makers.
278 but promising step toward providing specific prognoses to patients, families, and practitioners.
279 s, to determine the relationship of assigned prognoses to the clinical criteria commonly used in the
281 cell lines representing cancers with dismal prognoses, tumor metastases, and multidrug resistant cel
282 ates patients with heterogeneous statistical prognoses was developed in a cohort of 361 patients with
283 juvant therapy and are associated with worse prognoses.We investigated factors that might predispose
284 at improvement in prognoses and worsening in prognoses were both strongly associated with initial pro
285 erican Joint Committee on Cancer system, and prognoses were compared among different groups of the re
286 were not randomized, and patients with worse prognoses were disproportionately given the FA and TA re
289 sicians who were least confident about their prognoses were more likely to favor no disclosure over f
290 of four phenoclusters with distinct clinical prognoses were separately identified for death and the c
293 ximately 60% spontaneous survival), and poor prognoses with drug-induced ALF, hepatitis B, and indete
294 ients with advanced CKD tended to have worse prognoses with elevated troponin I levels than those wit
295 the ABC or GCB subtype of DLBCL had similar prognoses with MYC/BCL2 coexpression and without MYC/BCL
296 ere generally less accurate than clinicians' prognoses, with lower AUC values for most outcomes.
297 valuating and comprehending nomogram-derived prognoses, with particular emphasis on clarifying common
299 iling identified AML patients with divergent prognoses within the FLT3-MU group, and the RUNX3 to ATR
300 apsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transpla